ize innovative therapies for patients with cardiorenal diseases. Tenapanor is one such therapy, and its acceptance by China's Center for Drug Evaluation is a significant achievement for Ardelyx. With the NDA submission expected to be approved by the end of 2024, this marks a major milestone in bringing tenapanor to patients in China. Ardelyx CEO expresses gratitude towards collaboration partner ..
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company specializing in therapies for chronic inflammatory diseases, unveiled additional findings from its pivotal trial for atopic dermatitis during the 2023 World Congress of Dermatology. The data highlighted the effectiveness and safety of rademikibart (formerly known as CBP-201) in treating moderate-to-severe atopi..
중국의 HUTCHMED는 HMPL-415라는 새로운 약물의 상이 활성점 저해제로 작용하는 알로스테릭 선택적 저해제인 SHP2를 대상으로 한 1상 연구를 개시했다고 발표했다. 이 임상시험은 고도의 악성 고형 종양을 가진 환자를 대상으로 HMPL-415의 안전성, 내성, 약동학 및 예비 효능 프로파일을 평가하는 연구이며, 약 80명의 환자를 예상하고 있다. 이 연구는 중증도 증가 단계의 일부로 환자를 포함하고, 추천된 2상 용량이 결정된 이후 추가 환자를 모집할 예정이다. HMPL-415의 대표적인 주요 조사원은 중산 병원 중대학의 텐슈 류 박사와 훈난 암병원의 논 앙 박사이다. 자세한 내용은 clinicaltrials.gov에서 NCT05886374 식별자를 사용하여 확인할 수 있다.
InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and effi..
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2..
National Cancer Center Announces Recipients of 2023-24 Research Fellowship Awards The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research. This year’s class of 15 recipients—six first-time awards and nine renewals—hail from China, India, Bangladesh, Italy, Mexico, South..
Clinical stage AI drug discovery company, MindRank, has announced the start of its first-in-human (FIH) Phase 1 study of MDR-001 in China. The proprietary glucagon-like peptide 1 receptor agonist (GLP-1 RA), which is an oral small-molecule designed to treat obesity and type 2 diabetes mellitus (T2DM), was discovered using MindRank's Molecule Pro AI platform. The FIH Phase 1 trial will evaluate t..
China has approved the world's first vaccine against XBB descendent lineages of SARS-CoV-2 for emergency use. The Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine, developed by WestVac Biopharma/West China Medical Center, Sichuan University, is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants locally and internationally, inc..
